Vitamin K antagonists have been used for many years as the treatment of choice for long-
term oral anticoagulation in patients with non-valvular atrial fibrillation. Unfortunately, the …

Atrial high-rate episodes (AHRE) are atrial tachyarrhythmias detected by continuous rhythm
monitoring by pacemakers, defibrillators, or implantable cardiac monitors. Atrial high-rate …

Aims Direct oral anticoagulants (DOAC) are progressively replacing vitamin K antagonists in
the prevention of thromboembolism in patients with atrial fibrillation. However, their real …

Background and purpose Prospectively collected data comparing the safety and
effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective …

Background Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …

Objective In patients with newly diagnosed atrial fibrillation (AF), do baseline risk factors and
stroke prevention strategies account for the geographically diverse outcomes. Design Global …

Background The outcomes of patients newly diagnosed with atrial fibrillation (AF) following
the introduction of direct-acting oral anticoagulants are not well known. Aim To determine …

Objective There is a substantial incidence of stroke in patients with atrial fibrillation (AF) not
receiving anticoagulation. The reasons for not receiving anticoagulation are generally …

Background Nursing home residents with atrial fibrillation are at high risk for ischemic stroke,
but most are not treated with anticoagulants. This study compared the effectiveness and …

Background The extent to which differences in results from Apixaban for Reduction in Stroke
and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Rivaroxaban Once …